EA201991385A1 - Анти-gpc3-антитело - Google Patents
Анти-gpc3-антителоInfo
- Publication number
- EA201991385A1 EA201991385A1 EA201991385A EA201991385A EA201991385A1 EA 201991385 A1 EA201991385 A1 EA 201991385A1 EA 201991385 A EA201991385 A EA 201991385A EA 201991385 A EA201991385 A EA 201991385A EA 201991385 A1 EA201991385 A1 EA 201991385A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- gpc3
- antibody
- car
- gene
- single chain
- Prior art date
Links
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 abstract 4
- 102100032530 Glypican-3 Human genes 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 101150058049 car gene Proteins 0.000 abstract 2
- 210000000170 cell membrane Anatomy 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 238000011895 specific detection Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000048373 human GPC3 Human genes 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464474—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
Abstract
Объектом настоящего изобретения является анти-GPC3 антитело, которое распознает эпитоп, отличный от эпитопов для существующих антител (например, GC33 и GC199) и может специфически связываться, даже в форме одноцепочечного антитела, с GPC3, расположенного на клеточной мембране; CAR, содержащий анти-GPC3 одноцепочечное антитело; иммунокомпетентная клетка, экспрессирующая CAR; ген анти-GPC3 антитела или ген CAR; вектор, содержащий ген анти-GPC3 антитела или ген CAR; клетка-хозяин, в которую введен вектор; способ для специфической детекции GPC3 и набор для специфической детекции GPC3. Антитело, содержащее конкретные CDR1-CDR3 тяжелой цепи и конкретные CDR1-CDR3 легкой цепи по п.1, и специфически связывающееся с полипептидом GPC3 человека, локализованного на клеточной мембране. CAR-иммунокомпетентные клетки, полученные на основе CAR, содержащие такое одноцепочечное антитело, для применения в иммунотерапии злокачественных новообразований.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017001732 | 2017-01-10 | ||
PCT/JP2018/000257 WO2018131586A1 (ja) | 2017-01-10 | 2018-01-10 | 抗gpc3抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991385A1 true EA201991385A1 (ru) | 2019-12-30 |
Family
ID=62839598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991385A EA201991385A1 (ru) | 2017-01-10 | 2018-01-10 | Анти-gpc3-антитело |
Country Status (14)
Country | Link |
---|---|
US (3) | US11718663B2 (ru) |
EP (1) | EP3569709A4 (ru) |
JP (4) | JP6579640B2 (ru) |
KR (1) | KR102564097B1 (ru) |
CN (2) | CN110177876B (ru) |
AU (1) | AU2018208191A1 (ru) |
BR (1) | BR112019013947A2 (ru) |
CA (1) | CA3049189A1 (ru) |
EA (1) | EA201991385A1 (ru) |
IL (2) | IL300270A (ru) |
MA (1) | MA47268A (ru) |
MX (1) | MX2019008221A (ru) |
TW (2) | TWI831365B (ru) |
WO (1) | WO2018131586A1 (ru) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110177876B (zh) * | 2017-01-10 | 2023-03-31 | 国立大学法人山口大学 | 抗gpc3抗体 |
US11708401B2 (en) | 2018-06-22 | 2023-07-25 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
WO2020017479A1 (ja) * | 2018-07-17 | 2020-01-23 | ノイルイミューン・バイオテック株式会社 | 抗gpc3一本鎖抗体を含むcar |
WO2020072546A2 (en) * | 2018-10-01 | 2020-04-09 | Adicet Bio, Inc. | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS |
CN111040036B (zh) * | 2018-10-12 | 2023-10-20 | 上海卡智生物技术有限公司 | 抗gpc3单克隆抗体、由其修饰的免疫效应细胞及其应用 |
CN109504660B (zh) * | 2018-11-02 | 2021-08-06 | 温州启星生物技术有限公司 | 一种第四代car-t细胞及其构建方法和应用 |
CN112574297B (zh) * | 2019-09-27 | 2022-06-24 | 上海生物制品研究所有限责任公司 | 抗神经氨酸酶的单克隆抗体及其应用 |
WO2021110095A1 (zh) * | 2019-12-05 | 2021-06-10 | 上海翰森生物医药科技有限公司 | 抗gpc3抗体、其抗原结合片段及其医药用途 |
US20230088461A1 (en) * | 2020-02-27 | 2023-03-23 | Nanjing Legend Biotech Co., Ltd. | Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof |
KR20220155589A (ko) * | 2020-03-18 | 2022-11-23 | 주식회사 유틸렉스 | Il-18을 분비하는 gpc3 car-t 세포 및 이의 제조 및 사용 방법 |
KR20220155588A (ko) * | 2020-03-18 | 2022-11-23 | 주식회사 유틸렉스 | Gpc3 car-t 세포 조성물 및 이의 제조 및 사용 방법 |
US20240026037A1 (en) * | 2020-11-18 | 2024-01-25 | Memorial Sloan Kettering Cancer Center | Anti-gpa33 multi-specific antibodies and uses thereof |
KR20220080381A (ko) * | 2020-12-07 | 2022-06-14 | (주)이노베이션바이오 | Gpc3에 특이적인 항체 및 이의 용도 |
CN113072643B (zh) * | 2021-03-22 | 2021-10-15 | 南京医科大学 | 抗Glypican-3耐酸性全人源抗体、其免疫毒素、其嵌合抗原受体细胞及应用 |
EP4313131A1 (en) * | 2021-03-28 | 2024-02-07 | Immunome, Inc. | Il-38-specific antibodies |
AU2022291365A1 (en) * | 2021-06-08 | 2024-01-18 | Kite Pharma, Inc. | Gpc3 binding molecules |
WO2022268196A1 (zh) * | 2021-06-25 | 2022-12-29 | 天辰生物医药(苏州)有限公司 | 靶向gpc3的抗原结合蛋白 |
CN113527500B (zh) * | 2021-07-16 | 2022-09-20 | 蒋小滔 | 一种磷脂酰肌醇蛋白聚糖3的全人源单克隆抗体、其嵌合抗原受体及应用 |
EP4372089A1 (en) * | 2021-07-16 | 2024-05-22 | Noile-Immune Biotech Inc. | Chimeric antigen receptor, cell capable of expressing said receptor, pharmaceutical composition containing said cell, method for producing said cell, and polynucleotide or vector which contains nucleotide sequence encoding said chimeric antigen receptor |
WO2024118866A1 (en) * | 2022-12-01 | 2024-06-06 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
CN118063612A (zh) * | 2024-04-18 | 2024-05-24 | 上海宏成药业有限公司 | 抗ror1抗体或其抗原结合片段及其用途 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE255162T1 (de) | 1983-01-13 | 2003-12-15 | Max Planck Gesellschaft | Transgene dicotyledone pflanzenzellen und pflanzen |
NL8300698A (nl) | 1983-02-24 | 1984-09-17 | Univ Leiden | Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten. |
EP0164575B1 (de) | 1984-05-11 | 1992-03-18 | Novartis AG | Transformation von Pflanzenerbgut |
JPS62275650A (ja) | 1986-05-23 | 1987-11-30 | Hatsuho Seika Kk | 膨張菓子の製造方法 |
IL84459A (en) | 1986-12-05 | 1993-07-08 | Agracetus | Apparatus and method for the injection of carrier particles carrying genetic material into living cells |
JP2928287B2 (ja) | 1988-09-29 | 1999-08-03 | 協和醗酵工業株式会社 | 新規ポリペプチド |
JPH0322979A (ja) | 1989-06-19 | 1991-01-31 | Kyowa Hakko Kogyo Co Ltd | 新規プラスミノーゲン活性化因子 |
US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
WO2004022597A1 (ja) | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドに対する抗体 |
WO2004023145A1 (ja) * | 2002-09-04 | 2004-03-18 | Perseus Proteomics Inc. | Gpc3の検出による癌の診断方法 |
PL1674111T3 (pl) | 2004-07-09 | 2011-04-29 | Chugai Pharmaceutical Co Ltd | Przeciwciała anty-glipikan 3 |
EP2699603B1 (en) | 2011-04-19 | 2016-03-02 | The United States of America As Represented by the Secretary Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
WO2013070468A1 (en) * | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
CN104520331B (zh) | 2012-06-01 | 2018-09-07 | 美国政府(由卫生和人类服务部的部长所代表) | 磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途 |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
CN104140974B (zh) | 2013-05-08 | 2017-09-29 | 科济生物医药(上海)有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
CN105849562B (zh) * | 2013-12-24 | 2019-08-16 | 中外制药株式会社 | 可溶性gpc3蛋白质的测定方法 |
JP2017522861A (ja) * | 2014-05-22 | 2017-08-17 | ジェネンテック, インコーポレイテッド | 抗gpc3抗体及びイムノコンジュゲート |
WO2016036973A1 (en) * | 2014-09-04 | 2016-03-10 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
ES2844700T3 (es) | 2014-09-26 | 2021-07-22 | Baylor College Medicine | Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva |
SG11201702391RA (en) | 2014-10-09 | 2017-04-27 | Univ Yamaguchi | Car expression vector and car-expressing t cells |
JP6558091B2 (ja) | 2015-06-15 | 2019-08-14 | 大日本印刷株式会社 | 注出口組合体、注出口組合体付容器、及び充填体 |
CN110177876B (zh) * | 2017-01-10 | 2023-03-31 | 国立大学法人山口大学 | 抗gpc3抗体 |
-
2018
- 2018-01-10 CN CN201880006069.1A patent/CN110177876B/zh active Active
- 2018-01-10 WO PCT/JP2018/000257 patent/WO2018131586A1/ja unknown
- 2018-01-10 CN CN202310167019.4A patent/CN116102651A/zh active Pending
- 2018-01-10 JP JP2018561377A patent/JP6579640B2/ja active Active
- 2018-01-10 TW TW111134012A patent/TWI831365B/zh active
- 2018-01-10 IL IL300270A patent/IL300270A/en unknown
- 2018-01-10 MX MX2019008221A patent/MX2019008221A/es unknown
- 2018-01-10 KR KR1020197019505A patent/KR102564097B1/ko active IP Right Grant
- 2018-01-10 AU AU2018208191A patent/AU2018208191A1/en active Pending
- 2018-01-10 EP EP18738824.4A patent/EP3569709A4/en active Pending
- 2018-01-10 MA MA047268A patent/MA47268A/fr unknown
- 2018-01-10 US US16/472,356 patent/US11718663B2/en active Active
- 2018-01-10 EA EA201991385A patent/EA201991385A1/ru unknown
- 2018-01-10 CA CA3049189A patent/CA3049189A1/en active Pending
- 2018-01-10 TW TW107100996A patent/TWI780102B/zh active
- 2018-01-10 BR BR112019013947-8A patent/BR112019013947A2/pt unknown
-
2019
- 2019-07-02 IL IL267797A patent/IL267797B2/en unknown
- 2019-08-21 US US16/546,787 patent/US10781249B2/en active Active
- 2019-08-22 JP JP2019151869A patent/JP6647675B2/ja active Active
- 2019-12-27 JP JP2019237695A patent/JP2020074776A/ja active Pending
-
2022
- 2022-10-03 JP JP2022159364A patent/JP7389424B2/ja active Active
-
2023
- 2023-06-15 US US18/335,477 patent/US20240018224A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10781249B2 (en) | 2020-09-22 |
MX2019008221A (es) | 2019-12-09 |
EP3569709A4 (en) | 2020-08-19 |
MA47268A (fr) | 2019-11-20 |
KR102564097B1 (ko) | 2023-08-04 |
JP2019216739A (ja) | 2019-12-26 |
US20190367634A1 (en) | 2019-12-05 |
CA3049189A1 (en) | 2018-07-19 |
US11718663B2 (en) | 2023-08-08 |
JP6579640B2 (ja) | 2019-09-25 |
TW202309098A (zh) | 2023-03-01 |
WO2018131586A1 (ja) | 2018-07-19 |
TW201831516A (zh) | 2018-09-01 |
BR112019013947A2 (pt) | 2020-02-11 |
IL267797A (en) | 2019-10-31 |
IL267797B1 (en) | 2023-03-01 |
JP7389424B2 (ja) | 2023-11-30 |
CN110177876B (zh) | 2023-03-31 |
EP3569709A1 (en) | 2019-11-20 |
CN116102651A (zh) | 2023-05-12 |
US20190359698A1 (en) | 2019-11-28 |
JPWO2018131586A1 (ja) | 2019-11-07 |
KR20190101989A (ko) | 2019-09-02 |
JP2022191318A (ja) | 2022-12-27 |
CN110177876A (zh) | 2019-08-27 |
IL267797B2 (en) | 2023-07-01 |
TWI831365B (zh) | 2024-02-01 |
US20240018224A1 (en) | 2024-01-18 |
JP2020074776A (ja) | 2020-05-21 |
JP6647675B2 (ja) | 2020-02-14 |
AU2018208191A1 (en) | 2019-07-04 |
TWI780102B (zh) | 2022-10-11 |
IL300270A (en) | 2023-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991385A1 (ru) | Анти-gpc3-антитело | |
MX2020009774A (es) | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. | |
PH12017500483A1 (en) | Method for the absolute qualification of naturally processed hla-restircted cancer peptides | |
MX2020010235A (es) | Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos. | |
EA202090247A1 (ru) | Антитела против cd166 и их применения | |
TR201910814T4 (tr) | Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri. | |
MX361502B (es) | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano. | |
EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
EA202190608A1 (ru) | Однодоменные анти-bcma антитела и их применение | |
PH12018502293A1 (en) | Humanized anti-basigin antibodies and the use thereof | |
EA201690299A1 (ru) | СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ | |
EA201500741A1 (ru) | ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ | |
MX2021015033A (es) | Clasificacion con contraseleccion utilizando peptidos de secuencias similares. | |
GB201212940D0 (en) | Antibodies to highly conserved targets | |
MX2022000652A (es) | Anticuerpos contra claudina 18 y metodos de tratamiento del cancer. | |
EA201892325A1 (ru) | Композиции и способы детектирования белков клетки-хозяина | |
MX2018013081A (es) | Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia. | |
WO2015112558A3 (en) | Peptides, devices, and methods for the detection of anaplasma antibodies | |
MX2021012030A (es) | Instrumentacion automatizada para la produccion de bibliotecas de peptidos de receptores de celulas t. | |
MX2021002125A (es) | Receptores de celulas t restringidos a mr1 para inmunoterapia contra el cancer. | |
EA202091488A1 (ru) | Иммунокомпетентная клетка, которая экспрессирует молекулу клеточной поверхности, специфически распознающую человеческий мезотелин, il-7 и ccl19 | |
EP4300101A3 (en) | Antigenic peptides and uses thereof for diagnosing and treating autism | |
MX2016010995A (es) | Novedoso anticuerpo anti-presepsina. | |
WO2019025865A3 (en) | METHODS AND COMPOSITIONS FOR LIGAND-DIRECTED ANTIBODY DESIGN | |
MX2019003288A (es) | Proteínas de mycobacterium tuberculosis en pruebas diagnósticas y dispositivos para la detección y diagnóstico de la tuberculosis. |